Gene Interactions: Developing a taxonomy for colorectal cancer

Analyzing how gene interaction networks are perturbed in individuals can help identify different types of colorectal cancers, paving the way towards personalized care.
  1. Jiansong Fang
  2. Dawei Wang
  3. Xiude Fan  Is a corresponding author
  1. Guangzhou University of Chinese Medicine, China
  2. Department of Endocrinology, Shandong Provincial Hospital, Shandong University, China
  3. Department of Endocrinology, Shandong Provincial Hospital, Shandong Provincial Hospital, China

Colorectal cancer is challenging to treat because different patients have widely varying symptoms and the cancers display a broad range of molecular characteristics (Guinney et al., 2015). What can researchers and clinicians do to overcome these obstacles? First, it is necessary to understand the biological properties that make each type of colorectal cancer different, and to establish a precise molecular classification for the different subtypes based on these differences. This will help researchers to develop effective drug interventions. In the past decade, many diseases have been classified based on their transcriptome. However, this ignores the fact that levels of gene expression can vary widely in living patients (Wang et al., 2019).

Now, in eLife, Zhenqiang Sun, Xinwei Han and colleagues at the First Affiliated Hospital of Zhengzhou University – including with Zaoqu Liu as first author – report how they have developed a taxonomy for colorectal cancers based on the interactions between genes rather than on the levels of gene expression (Liu et al., 2022). This approach analyzes networks of gene interactions, which tend to be conserved in healthy samples, but are perturbed in cancer. This makes it possible to characterize the different types of tumors based on how their gene interaction networks are perturbed.

First, the researchers. used a dataset including tumors and healthy samples to generate a large-scale network that had genes as the nodes of the network, and the interactions between genes as the edges. Next, for both healthy and cancerous samples, they quantified the level of perturbation by measuring how the interactions between each pair of genes in the network had changed.

This analysis showed that the perturbations were much stronger in the tumors. Moreover, using a computational approach called clustering analysis, Liu et al. were able to establish six subtypes of colorectal cancers, which they called gene interaction-perturbation network subtypes (or GINS for short; Figure 1). Comparing this new taxonomy with previously published classifications of colorectal cancers revealed that there are notable differences between GINS and subtypes from other taxonomies (Figure 1). Liu et al. were able to confirm the stability and reproducibility of their proposed classification by validating it in independent datasets, which suggests that this taxonomy will be extremely useful for clinical applications.

A new taxonomy for colorectal cancer.

Liu et al. identified six subtypes of colorectal cancer: GINS1 is a proliferative subtype (green); GINS2 is a stromal-rich subtype (yellow); GINS3 is a KRAS-inactivated subtype (grey); GINS4 is a mixed subtype (red); GINS5 is an immune-activated subtype (bright blue); and GINS6 is a metabolic reprogramming subtype (dark blue). Liu et al. report that GINS4 is an intermediate state between the GINS2 and GINS5 subtypes, which suggests that converting GINS4 into GINS5, which has a better prognosis and may be more sensitive to immunotherapy (especially to PARP inhibitors), might be a good treatment strategy. The GINS6 subtype, on the other hand, may respond well to statins based on its characteristics.

A good molecular classification needs to convey clear biological interpretations of the underlying data, as this will help lay the ground for trials and treatments aimed at specific subtypes (Lin et al., 2021; Ten Hoorn et al., 2022; Singh et al., 2021). Along these lines, Liu et al. report distinguishing features for each of the six subtypes they have identified. For example, GINS1 is a proliferative subtype, whereas GINS2 is a stromal-rich subtype; Figure 1 has details on the other four subtypes.

Looking forward, the new taxonomy will need to be validated by further studies in different populations. Additionally, the classification could be improved by integrating multi-omics data – such as transcriptomic data and proteomic data – into the network. In recent years, the HuRI and BioPlex initiatives have provided comprehensive human interactomes at the proteome level, improving our understanding of genotype-phenotype relationships (Luck et al., 2020; Huttlin et al., 2021). These could be used to make the new perturbation network more robust. Finally, it might also be possible to apply the new network to other challenges, for example, to identify new therapeutic agents for colorectal cancer through network-based approaches (Fang et al., 2021).

The work of Liu et al. is another example of the use of network-based approaches to classify cancer subtypes, such as the recent molecular taxonomy developed for meningioma (Nassiri et al., 2021). The results present and validate a new classification system for colorectal cancer, providing more insights into the heterogeneity of the disease, and facilitating both translational research and personalized approaches to treatment.


Article and author information

Author details

  1. Jiansong Fang

    Jiansong Fang is in the Department of Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6998-5384
  2. Dawei Wang

    Dawei Wang is in the Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7902-001X
  3. Xiude Fan

    Xiude Fan is in the Department of Endocrinology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, China

    For correspondence
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7413-080X

Publication history

  1. Version of Record published: November 11, 2022 (version 1)


© 2022, Fang et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 309
    Page views
  • 25
  • 0

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jiansong Fang
  2. Dawei Wang
  3. Xiude Fan
Gene Interactions: Developing a taxonomy for colorectal cancer
eLife 11:e84025.

Further reading

    1. Cancer Biology
    Samantha C Schwager, Katherine Young ... Cynthia A Reinhart-King
    Research Article

    Cancer cell migration is highly heterogeneous, and the migratory capability of cancer cells is thought to be an indicator of metastatic potential. It is becoming clear that a cancer cell does not have to be inherently migratory to metastasize, with weakly migratory cancer cells often found to be highly metastatic. However, the mechanism through which weakly migratory cells escape from the primary tumor remains unclear. Here, utilizing phenotypically sorted highly and weakly migratory human breast cancer cells, we demonstrate that weakly migratory metastatic cells disseminate from the primary tumor via communication with stromal cells. While highly migratory cells are capable of single cell migration, weakly migratory cells rely on cell-cell signaling with fibroblasts to escape the primary tumor. Weakly migratory cells release microvesicles rich in tissue transglutaminase 2 (Tg2) which activate murine fibroblasts and lead weakly migratory cancer cell migration in vitro. These microvesicles also induce tumor stiffening and fibroblast activation in vivo and enhance the metastasis of weakly migratory cells. Our results identify microvesicles and Tg2 as potential therapeutic targets for metastasis and reveal a novel aspect of the metastatic cascade in which weakly migratory cells release microvesicles which activate fibroblasts to enhance cancer cell dissemination.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Luca Costantino, Stefania Ferrari ... Maria Paola Costi
    Research Article

    Drugs that target human thymidylate synthase (hTS), a dimeric enzyme, are widely used in anti-cancer therapy. However, treatment with classical substrate-site-directed TS inhibitors induces over-expression of this protein and development of drug resistance. We thus pursued an alternative strategy that led us to the discovery of TS-dimer destabilizers. These compounds bind at the monomer-monomer interface and shift the dimerization equilibrium of both the recombinant and the intracellular protein toward the inactive monomers. A structural, spectroscopic, and kinetic investigation has provided evidence and quantitative information on the effects of the interaction of these small molecules with hTS. Focusing on the best among them, E7, we have shown that it inhibits hTS in cancer cells and accelerates its proteasomal degradation, thus causing a decrease in the enzyme intracellular level. E7 also showed a superior anticancer profile to fluorouracil in a mouse model of human pancreatic and ovarian cancer. Thus, over sixty years after the discovery of the first TS prodrug inhibitor, fluorouracil, E7 breaks the link between TS inhibition and enhanced expression in response, providing a strategy to fight drug-resistant cancers.